Utility and Appropriate Use of PCSK9 Inhibitors in the Current Era
Atherosclerotic cardiovascular diseases (ASCVD) remain the number one cause of death and morbidity in the country. Elevated cholesterol/hyperlipidemia has been considered one of the major risk factors for ASCVD. Statins have been the main stay therapy for treating hyperlipidemia achieving remarkable...
Guardado en:
| Autores principales: | , , |
|---|---|
| Formato: | Capítulo de libro |
| Lenguaje: | inglés |
| Publicado: |
IntechOpen
2021
|
| Materias: | |
| Acceso en línea: | https://www.intechopen.com/chapters/74389 |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares: Utility and Appropriate Use of PCSK9 Inhibitors in the Current Era
- Eficacia, seguimiento y aplicabilidad clínica de los Inhibidores de PCSK9
- Treatment of Chronic HCV Infection in the Era of Protease Inhibitors
- Neoadjuvant Immune Checkpoint Inhibitors and Antibody-Drug Conjugates in Urothelial Carcinoma: Current Evidence and Future Perspectives
- The Use of Artemisinin Compounds as Angiogenesis Inhibitors to Treat Cancer
- Farnesyltransferase Inhibitor in Cancer Treatment
- PARP Inhibitors in Ovarian Cancer